Cannabidiol is without a doubt the breakout star among medicines this decade, if not the century. The cannabis extract is a darling of the medicine, sports, and the health and wellness communities, with potent and versatile medicinal properties that make it effective against a wide range of diseases. A lot of people use it for pain and anxiety relief, but anecdotally, CBD has worked against high blood pressure, improved sleep and reduced seizures in people with epilepsy. In June 2018, the FDA approved a CBD-based medication to help manage seizures in rare forms of childhood epilepsy.
Recently the UK National Health Service (NHS) approved the use of two CBD-based drugs for use in the United Kingdom, Epidiolex and Sativex. Sativex is a mouth spray used to treat multiple sclerosis-related muscle stiffness and spasms. Epidyolex, on the other hand, was approved for use by children with two rare and hard to manage forms of epilepsy, Dravet syndrome, and Lennox Gastaut syndrome. Geraldine Woodman is one of the people who were greatly affected by this news.
The 43-year-old mum has an 8-year-old son, Eddie. He was born two weeks premature, and he had a bleed on his brain. Despite this, he developed normally, but when he was nine months old, he suffered a seizure and upon hospitalization, he was diagnosed with infantile spasms, an aggressive form of epilepsy. “Ever since that day, they kept giving him medication to knock him out because every time he’d open his eyes he’d have a seizure,” she says.
“Within 20 seconds of him waking up, you would see him have a cluster of seizures for around an hour.” He was taking 60mg of drugs a day by the time he was 6, leaving him ‘zonked out’ and staring into space. The side effects weren’t pretty, and even more drugs were prescribed to address them. He lost most of his eyesight (he could only see lights) and most of the time he was in a zombie-like vegetative state. Desperate for a better alternative for her son, she went against her doctor’s advice and tried CBD oil.
She says his symptoms have drastically reduced since then, and he “has the sparkle back in his eyes.” According to Geraldine, he giggles, loves swimming and squeals with delight when pushed on a swing. Previously, he would have barely flinched. “We can see it when we look in his eyes, they have that sparkle back. Now he makes a lot of noise, he’s a big talker, he’s calm in class, he does swimming and music.” His pharmaceutical intake has gradually reduced to just 1mg.
“It’s not a cure but it is giving him an alternative so he can have some quality of life instead of being on a pharmaceutical rollercoaster where he can’t function.”
One would be driven to imagine that such stories as the one of this little boy are what keep CBD companies like The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) and Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) working hard to formulate even better products so that more people in need can find some relief from their conditions.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
